Pivotal Phase II study showed Roche’s investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer

Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer. Roche will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab's Breakthrough Therapy Designation in lung cancer Roche today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person's cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab. "We are encouraged by the number of people who responded to atezolizumab and maintained their response during the study, which is particularly meaningful for people who had received several prior treatments," said Sandra Horning, M.D. Chief Medical Officer and head of Global Product Development. "We plan to present results at an upcoming medical meeting and will discuss these data as well as results from our other lung cancer studies with health authorities to bring this medicine to patients as quickly as possible.'' Earlier this year, the FDA granted atezolizumab a Breakthrough Therapy Designation for the treatment of people whose NSCLC expresses PD-L1 and who progressed during or after standard treatments (e.g.